3-[4-ethoxy-5-methyl-2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]-3H-1,3-oxazol-2-yl]phenol

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-[4-ethoxy-5-methyl-2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]-3H-1,3-oxazol-2-yl]phenol
• 化学式: C₂₄H₃₅N₅O₃S
• 分子量: 473.6
• InChiKey: WFBAKBFCYSQNTJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  120
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS
  申请人：Novartis AG

  公开号：EP2948448A1

  公开（公告）日：2015-12-02
• COMPOUNDS FOR THE TREATMENT OF CANCER
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3256126A1

  公开（公告）日：2017-12-20
• METHODS FOR TREATING HUNTINGTON'S DISEASE
  申请人：PTC Therapeutics, Inc.

  公开号：EP3386511B1

  公开（公告）日：2021-05-12
• [EN] THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS<br/>[FR] COMPOSÉS DE THIADIAZOLE, ANALOGUES DE CEUX-CI ET MÉTHODES DESTINÉES À TRAITER LES AFFECTIONS LIÉES À UN DÉFICIT EN SMN
  申请人：NOVARTIS AG

  公开号：WO2014116845A1

  公开（公告）日：2014-07-31

  The present invention provides a compound of Formula (X) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
• [EN] COMPOUNDS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS POUR LE TRAITEMENT D'UN CANCER
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016128343A1

  公开（公告）日：2016-08-18

  The present invention relates to a FoxM1 gene splicing modifier selected from a compound of formula (I) or of formula (VI), wherein A and B are as defined herein, or a pharmaceutically acceptable salt thereof, for use in the treatment, prevention and/or delay of progression of cancer.